Showing results (2041-2050 of 13,175) with videos related to
Sort By:
Pageof 1,318
Diabetes Care|September 29, 2004
Increasing prevalence of the metabolic syndrome among u.s. AdultsEarl S Ford, Wayne H Giles, Ali H MokdadDiabetes Care|September 29, 2004
Is patient readiness to change a predictor of improved glycemic control?Patrick J O'Connor, Stephen E Asche, A Lauren Crain, et al.Diabetes Care|September 29, 2004
Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetesAndrew J Sommerfield, Ian J Deary, Brian M FrierDiabetes Care|July 27, 2005
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathyGen Yasuda, Daisaku Ando, Nobuhito Hirawa, et al.Diabetes Care|June 29, 2005
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaRonald B Goldberg, David M Kendall, Mark A Deeg, et al.Diabetes Care|April 29, 2004
The burden of diabetes-associated cardiovascular hospitalizations in Veterans Administration (VA) and non-VA medical facilitiesNicholas L Smith, Charles MaynardDiabetes Care|April 29, 2004
Diabetes and renal disease in veteransBessie A Young, Jacqueline A Pugh, Charles Maynard, et al.Diabetes Care|April 29, 2004
Diabetes research in the Department of Veterans AffairsGayle E Reiber, Edward J BoykoDiabetes Care|July 28, 2004
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal diseaseAndrew J Palmer, Lieven Annemans, Stéphane Roze, et al.Diabetes Care|July 28, 2004
Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular diseaseMartin Magnusson, Olle Melander, Bo Israelsson, et al.Pageof 1,318